Background and Purpose-In patients with atrial fibrillation (AF), stroke risk stratification schema do not consider AF parameters. The aim of the study is to assess the impact of combining risk factors with continuous AF burden monitoring. Methods-In this retrospective study 568 patients implanted with a DDDR-P pacemaker (AT-500; Medtronic) and a history of AF were continuously monitored for 1 year. Results-During follow-up, 14 patients (2.5%) had a thromboembolic event. Patients were divided into 3 groups: AF burden Յ5 minutes per day (AF-free; nϭ223 Key Words: anticoagulation Ⅲ antithrombotics Ⅲ atrial fibrillation Ⅲ embolic stroke Ⅲ heart-brain relationships Ⅲ platelet inhibitors Ⅲ prevention Ⅲ prognosis T he burden of atrial fibrillation (AF) and the duration of arrhythmia episodes have never been included in risk stratification schemes because reliance on clinical symptoms and intermittent electrocardiographic assessments can underestimate AF burden. 1,2 Diagnostic features in implantable devices are sophisticated enough to provide reliable information on atrial arrhythmias, allowing data to generate hypotheses on stroke risk stratification. [1] [2] [3] [4] The aim of the study is to test the hypothesis that continuous AF burden monitoring would enhance the sensitivity/specificity of stroke risk stratification schema based on clinical risk factors.
T he burden of atrial fibrillation (AF) and the duration of arrhythmia episodes have never been included in risk stratification schemes because reliance on clinical symptoms and intermittent electrocardiographic assessments can underestimate AF burden. 1, 2 Diagnostic features in implantable devices are sophisticated enough to provide reliable information on atrial arrhythmias, allowing data to generate hypotheses on stroke risk stratification. [1] [2] [3] [4] The aim of the study is to test the hypothesis that continuous AF burden monitoring would enhance the sensitivity/specificity of stroke risk stratification schema based on clinical risk factors.
Methods
Patients with a dual-chamber pacemaker (Medtronic AT-500) and a history of paroxysmal atrial tachyarrhythmias were included into this study. A day-by-day trend of AF burden (ϭtime spent in AF during each day) was available for each patient during 1-year follow-up with data on minutes/hour spent at high atrial rates. 2 Patients were divided into 3 groups: (1) maximum AF burden Յ5 minutes per day (AF-free); (2) maximum AF burden Ͼ5 minutes but Ͻ24 hours per day (AF-5 minutes); and (3) AF burden of Ն24 hours, the latter considering also the following days (AF-24 hours). Patients were also classified according to the CHADS 2 and the CHA 2 DS 2 -VASc 5 risk scores. A committee of 2 physicians, blinded to AF burden, evaluated the thromboembolic events (TEs): stroke, transient ischemic attack, and peripheral arterial embolism.
Sensitivity and specificity of each score in predicting TE events, either alone or in combination with AF, were assessed. The number of patients who would require long-term oral anticoagulation therapy (OAC) was calculated according to each combination. Uni-and multivariable logistic regressions were performed considering the CHADS 2 and the CHA 2 DS 2 -VASc scores as continuous variables, whereas AF burden was analyzed by class. For each regression model, the predicted probabilities were used to assess the discriminatory ability of each risk score by means of the C-statistic and its 95% CI. Statistical analysis was made by SPSS (SPSS Inc, Chicago, IL) software, Version 11.5.
Results
Data from 568 patients (70Ϯ10 years) were analyzed. Patients were categorized into 3 AF groups: AF-free (nϭ223 [39%]), AF-5 minutes (nϭ179 [32%]), and AF-24 hours (nϭ166 [29%]). In groups AF-free, AF-5 minutes, and AF-24 hours, respectively, aspirin was prescribed in 30%, 23%, and 18%; OAC in 19%, 22%, and 42%; and aspirin and OAC in 6%, 1.7%, and 4%. OAC use was higher in the AF-24 hours group versus AF-free or AF-5 minutes (PϽ0.0001).
Fourteen patients (2.5%) had a TE (cerebral embolism: 12; peripheral embolism: 2). Table 1 shows the baseline characteristics of the patient population. Sensitivity, specificity, and C-statistic for CHADS 2 score, CHA 2 DS 2 -VASc score, and their combination with AF data are summarized in Table 2 .
Compared with CHADS 2 score alone, its combination with AF parameters gave the best compromise between sensitivity (79%) and specificity (63%). The CHA 2 DS 2 -VASc score alone had 100% sensitivity. However, its specificity was low: 7% and 24%, respectively. When combined with AF data, it increased specificity up to 42% without relevant changes in sensitivity. The Figure shows the percentage of candidates for OAC according to each schema.
Discussion
The major finding of this study is that risk stratification for stroke can be improved by combining either CHADS 2 or CHA 2 DS 2 -VASc score with AF parameters. CHA 2 DS 2 -VASc scheme has the highest sensitivity to predict TE; its integration with continuous AF burden improves specificity and the discriminating ability for TE. Thus, data on AF burden may refine risk stratification for stroke and this is evident even when OAC is more commonly prescribed, as expected, in patients with the highest AF burden.
The CHADS 2 score is a simple and widely used scheme; OAC is recommended in patients with a score Ն2. Greater uncertainty arises for those with a score of 0 to 1. 5 The CHA 2 DS 2 -VASc score is very helpful in this category of patients, 5 but its specificity is limited, thus identifying a high number of candidates for long-term OAC. Any method for additional improvement of risk stratification is of clinical interest, especially in low-risk patients in whom the risk of bleeding linked to OAC may be a clinical concern. 5 The study was performed in a relatively modest sample size and in a specific population with previous AF and sick sinus syndrome. The follow-up period was limited to 1 year. According to the hypothesis-generating nature of our findings, there is the need for further studies on larger cohorts.
Conclusions
The CHA 2 DS 2 -VASc score has a high sensitivity, indicating good predictive value for truly low-risk subjects for TE. Integration of AF presence/duration/burden has the potential to contribute to improved clinical risk stratification and its aid to clinical decision-making should be tested prospectively.
Figure.
Candidacy for oral anticoagulation (OAC) therapy in relation to CHADS 2 and CHA 2 DS 2 -VASc stroke risk stratification schema and atrial fibrillation burden.
